Welcome to our dedicated page for Reading Intl SEC filings (Ticker: RDI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cinema attendance metrics on one page, commercial property valuations on the next—Reading International’s SEC filings force you to switch mental gears every few paragraphs. If you’ve ever hunted through a 300-page document for screen-count data and rental income footnotes, you know the challenge. Stock Titan surfaces exactly what matters, turning those hybrid disclosures into concise, actionable insights.
Want the numbers fast? Our platform delivers AI-powered summaries for every filing type, updated in real time as they hit EDGAR. Whether you’re searching for "Reading International quarterly earnings report 10-Q filing," "Reading International insider trading Form 4 transactions," or "Reading International 8-K material events explained," you’ll find plain-language answers plus downloadable originals. The AI highlights segment revenue splits, flags property fair-value changes, and even decodes non-GAAP cinema metrics—so "understanding Reading International SEC documents with AI" stops being an aspiration and starts being routine.
Use cases span the spectrum: track "Reading International executive stock transactions Form 4" before major releases, compare concession margins quarter-over-quarter with our "Reading International earnings report filing analysis," or dig into "Reading International proxy statement executive compensation" without reading every appendix. You’ll also see a clean timeline of "Reading International Form 4 insider transactions real-time" alerts and a guided walk-through of the "Reading International annual report 10-K simplified." All filings, all in one place, all explained simply—so you spend less time parsing and more time deciding.
Form 4 filing overview: Director and 10% owner Norbert W. Bischofberger reported the disposal of all Kronos Bio (KRON) equity holdings on 20 June 2025. The transactions were executed in connection with the previously announced merger between Kronos Bio and Concentra Biosciences completed on 18 June 2025.
Key details
- Common shares disposed: 10,802,138 held directly plus an aggregate 1,055,000 shares held through five family trusts (each trust disposed 263,750 shares).
- Consideration per share: US $0.57 cash plus one non-transferable contingent value right (CVR) as defined in the merger agreement.
- Derivative positions: Four option grants (total = 1,967,854 options; strike prices US $1.08–30.78) became fully vested and were cancelled. Cash was paid only where the strike price was below US $0.57; underwater options were forfeited with no value.
- Resulting ownership: Following the transactions, Bischofberger reports zero common shares and zero outstanding options.
The filing confirms logistical completion of equity transfers required by the merger and removes the insider’s Section 16 reporting obligations once KRON ceases to trade publicly.
FAQ
What is the current stock price of Reading Intl (RDI)?
What is the market cap of Reading Intl (RDI)?
What are the primary business segments of Reading Intl Inc?
Which geographic markets does the company serve?
What does the Cinema Exhibition segment encompass?
How does the Real Estate segment contribute to the business model?
What distinguishes Reading Intl Inc from its competitors?
How does Reading Intl Inc generate revenue?
What are some key challenges the company faces?
How is the company positioned within its competitive landscape?
